LON:MXC Argent BioPharma (MXC) Share Price, News & Analysis → Nvidia CEO Says It Will Be “the Next Revolution” Beyond AI (From Banyan Hill Publishing) (Ad) Free MXC Stock Alerts GBX 21 0.00 (0.00%) (As of 04/25/2024) Add Compare Share Share Today's Range 20▼ 2250-Day Range 19▼ 23.7052-Week Range 13.10▼ 600Volume7,884 shsAverage Volume26,353 shsMarket Capitalization£9.21 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsHeadlinesStock AnalysisChartCompetitorsHeadlines Get Argent BioPharma alerts: Email Address Ad Banyan Hill PublishingNvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.Click on Adam's shiny forehead for more details. About Argent BioPharma Stock (LON:MXC)MGC Pharmaceuticals Limited provides phytomedicines worldwide. The company produces and supplies medicinal cannabis products; and non-cannabis phytomedicines. Its principal product candidates include CimetrA, which is in phase III clinical trial for the symptomatic treatment of early COVID-19; CannEpil, a phase IIb cannabis-based therapy for drug-resistant Epilepsy; and CogniCann that is in phase II clinical trial for the symptomatic relief of Dementia. In addition, the company provides Irnican that is in preclinical phase for the tetrahydrocannabinol, as well as offers ArtemiC and non-pharma products. Further, it offers consulting services, including clinical research services. MGC Pharmaceuticals Limited was founded in 2014 and is based in Subiaco, Australia.Read More MXC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MXC Stock News HeadlinesApril 14, 2024 | au.investing.comArgent BioPharma appoints Dr Shlomo Sadoun to advisory boardJanuary 30, 2024 | uk.investing.comMGC Pharmaceuticals Ltd (MXC)April 29, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.December 22, 2023 | au.investing.comMGC Pharmaceuticals raising additional US$500,000 via private placementDecember 20, 2023 | morningstar.comMGC Pharmaceuticals Ltd MXCDecember 19, 2023 | au.investing.comMGC Pharma receives Saudi approval for ArtemiCDecember 18, 2023 | au.investing.comMGC Pharmaceuticals granted Saudi FDA approval for ArtemiC™November 9, 2023 | msn.com‘Fully funded’ – MGC Pharma completes share consolidation and ~US$8 million cap raiseApril 29, 2024 | Banyan Hill Publishing (Ad)Nvidia CEO Says It Will Be “the Next Revolution” Beyond AINvidia’s CEO calls it the “next amazing revolution” … and even declared it “is going to be flat out of the biggest [revolution] ever.” Jeff Bezos, Bill Gates, and Mark Zuckerberg have invested billions in it.November 8, 2023 | proactiveinvestors.com.auMGC Pharma completes share placing and consolidationNovember 1, 2023 | proactiveinvestors.com.auMGC Pharmaceuticals clarifies share consolidation and new fundraiseNovember 1, 2023 | msn.com‘Unwavering Support’: MGC Pharma secures US$7.9 million from investors as looks to advance US FDA IND applicationsNovember 1, 2023 | proactiveinvestors.com.auMGC Pharmaceuticals to raise US$7.9 million to fund its...MGC Pharmaceuticals to raise US$7.9 million to fund its 12-month...September 26, 2023 | lse.co.ukSMALL-CAP WINNERS & LOSERS: MGC Pharma drops on restructuring planSeptember 26, 2023 | marketwatch.comMGC Pharmaceuticals London Shares Fall on Restructuring PlanSeptember 26, 2023 | au.investing.comMGC Pharmaceuticals proposes financial and capital restructuring planSee More Headlines Receive MXC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Argent BioPharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolLON:MXC CUSIPN/A CIKN/A Webmgcpharma.com.au Phone61-8-6555-2950FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (1.66) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-17,020,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-58.96% Debt Debt-to-Equity Ratio1,436.12 Current Ratio0.75 Quick RatioN/A Sales & Book Value Annual Sales£1.32 million Price / Sales6.98 Cash FlowN/A Price / Cash FlowN/A Book ValueGBX 4 per share Price / Book5.25Miscellaneous Outstanding Shares43,850,000Free FloatN/AMarket Cap£9.21 million OptionableNot Optionable Beta1.03 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Roby Reuven Zomer (Age 44)Co-Founder, CEO, MD & Executive Director Comp: $183.3kMr. Tom CairnsChief Accounting OfficerMs. Yifat SteuerDeputy CEO & COOMs. Nicole Ann GodresseGlobal Chief Sales OfficerMr. Amir PolakChief Pharmaceutical Development OfficerMs. Sabina SuljakovicHead of the Quality Assurance DepartmentDr. Nadya LisovoderChief Medical OfficerMs. Sasha FriedmanDeputy CEOYair TalChief Information Security OfficerMr. Robert ClementsChief Commercial OfficerMore ExecutivesKey CompetitorsShield TherapeuticsLON:STXChill Brands GroupLON:CHLLProvexisLON:PXSHellenic DynamicsLON:HELDTotallyLON:TLYView All Competitors MXC Stock Analysis - Frequently Asked Questions How have MXC shares performed in 2024? Argent BioPharma's stock was trading at GBX 27 at the beginning of the year. Since then, MXC shares have decreased by 22.2% and is now trading at GBX 21. View the best growth stocks for 2024 here. How do I buy shares of Argent BioPharma? Shares of MXC stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:MXC) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsNvidia CEO Says It Will Be “the Next Revolution” Beyond AIBanyan Hill PublishingCharles Payne’s Gift to Stock InvestorsUnstoppable ProsperityProtect Your Bank Account Before It’s Too LateWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press4 coins to be the “Next Bitcoin”True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Argent BioPharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
